The Shingles Vaccine Market Size was valued at USD 3.8 billion in 2023. The Shingles Vaccine industry is projected to grow from USD 4.1 billion in 2024 to USD 7.03 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.00% during the forecast period (2024 - 2032).
The increasing prevalence of herpes zoster, generally known as shingles among adults, is one of the primary market drivers propelling the market's expansion.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Emulation-based VZV glycoprotein E (gE) is available in the adjuvanted subunit immunization Shingrix. For the anticipation of shingles (herpes zoster) and postherpetic neuralgia (persevering nerve torment after shingles), it is endorsed to people 50 years old and more established. Because of the incredible proficiency of these vaccinations and their minimal side effects, it is normal for the Shingrix to order most of the portion of the overall industry. Also, over the projection period, there will be an ascent in the popularity of these vaccinations because of the development of information on the illness's suggestions and the number of nations that have endorsed Shingrix for use as a drug.
Additionally, the demand for these vaccinations is increased by the widespread Shingrix acceptance among industrialized nations in North America and Europe, which is driving the market CAGR. This vaccine was included in the national shingles vaccination program after receiving a license in the United Kingdom in September of 2021.
Vaccination against herpes zoster with booster doses has been demonstrated to greatly boost immunity and offer long-term protection against the disease and its aftereffects, such as postherpetic neuralgia. Among those who have already had vaccinations, this improved efficacy may raise demand for booster doses. Research shows that shingles protection diminishes with time as the immune system's reaction to the first shingles immunization waned. Recurrence of immunization is encouraged by booster doses since they strengthen and prolong immunity and offer long-term protection against shingles.
Putting more of a focus on preventative healthcare raises awareness of the value of immunization in avoiding illnesses like shingles. Demand for shingles vaccine rises as a result of public health campaigns and educational programs that enhance knowledge of the disease's dangers. Shingles are more common in older persons, especially as populations get older. By encouraging people, particularly seniors, to get vaccinated against shingles as a preventative strategy to preserve their health, the emphasis on preventive healthcare is driving the growth of the market.
Furthermore, shingles vaccinations are becoming more widely used across various regions because of the endorsements of market members and the arrival of new antibodies. The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia, for instance, endorsed SK Bioscience's biologics permitting application for the 'SKYZoster' in January 2023. Over the projection period, these endorsements are likely to extend the market by working with vaccination administrations in various regions.
Moreover, the extensive dissemination of Shingrix has increased further due to the recent approvals and launches of this vaccine in other locations. Shingrix, for example, submitted a regulatory application to Japan's MHLW in June 2022 to prevent shingles in people who are at-risk and older than 18 years old. Conversely, GSK introduced Shingrix in Singapore in January 2022 with the goal of preventing shingles nationwide. Thus driving the Shingles Vaccine market revenue.
Based on Product, the Shingles Vaccine market segmentation includes Shingrix, zostavax, and SKYZoster. In 2023, the Shingrix segment dominated the market because of the vaccine's exceptional effectiveness and the lack of any serious side effects. Shingrix is also anticipated to increase at the fastest rate during the prediction. The increasing recognition of the illness and the licensing of Shingrix vaccinations in different parts of the world are responsible for this upsurge in the segment's growth. The National Medical Products Administration of China approved Shingrix in May 2019 as a means of preventing shingles, for example.
The SKYZoster category is anticipated to be the fastest growing. Many factors support SKYZoster's growth. They include its approval in South Korea, its affordability compared to Zostavax, and its inclusion in the vaccination schedule of some South Korean regions. Furthermore, the continuing clinical studies of SKYZoster for commercialization and approval abroad are expected to serve as drivers for the market's growth in the years to come.
Figure 1: Shingles Vaccine Market by Product, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Shingles Vaccine market segmentation based on Vaccine Type, includes recombinant vaccine and live attenuated vaccine. In 2023, the recombinant vaccine category generated the most income. The recombinant vaccine's exceptional success in preventing adult cases of shingles has been a major factor in its supremacy. The CDC reports that two doses of Shingrix have shown over 90% effectiveness in preventing shingles in those 50 years of age and older. This has strengthened the recombinant vaccine's standing as the main option for battling the illness.
The Shingles Vaccine’s live attenuated vaccine segment market is anticipated to grow fastest during the forecast period. Because vaccination rates are growing in emerging nations, people are becoming more aware of the disease. Live attenuated vaccines are becoming increasingly limited for individuals with weakened immune systems, which is having a detrimental effect on their acceptance in the market. The category is expected to be driven over the projected period by the approval of SK Bioscience's vaccine, SKYZoster.
The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Shingles Vaccine market will dominate this market. The shingles vaccine market is supposed to increase during the forecast time frame because of many variables, including the public authority's recommendation to use the shingles vaccine, the presence of a high-level medical care foundation, and high patient consciousness of the vaccines' significance.
The high prevalence of chickenpox is remembered to support the requirement for shingles antibodies since the reactivation of the chickenpox infection brings about shingles. For example, in September 2022, Mexican wellbeing specialists revealed 21,060 contaminations of chickenpox 2022 (11,057 men and 10,003 ladies), a lot higher figure than in 2021, when 8,897 diseases were enlisted, addressing an increment of 137%. The high-frequency pace of chickenpox expands the risk of the occurrence of shingles.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: SHINGLES VACCINE MARKET SHARE BY REGION 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's Shingles Vaccine market accounts for the second-largest market share. Strong immunization campaigns and a developed healthcare system in Europe facilitate the widespread administration and distribution of shingles vaccines. The population's vaccination uptake is increased via easily accessible healthcare facilities and immunization clinics. Further, the German Shingles Vaccine market held the largest market share, and the UK Shingles Vaccine market was the fastest-growing market in the European region.
The Asia-Pacific Shingles Vaccine Market is expected to grow at the fastest CAGR from 2024 to 2032. This increase is linked to rising disposable incomes, improvements in healthcare policies, and a sizable population at high risk of developing shingles. Furthermore, the unmet medical requirements of the lower- and middle-income nations in the area are anticipated to drive market development. The promotion of Shingrix in a number of Asian countries hastened the expansion of the market in that region. Moreover, China’s Shingles Vaccine market held the largest market share, and the Indian Shingles Vaccine market was the fastest-growing market in the Asia-Pacific region.
Shingles Vaccine Key Market Players & Competitive Insights
The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the Shingles Vaccine market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Shingles Vaccine industry must offer reasonably priced products and services.
One of the main strategies manufacturers use in the worldwide Shingles Vaccine market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The Shingles Vaccine industry has recently provided some of the largest medical advantages. Major players in the Shingles Vaccine market, including GlaxoSmithKline plc., Merck & Co., Inc., SK Chemicals, Green Cross Corp, Geneone Life Science, Vaccitech, CanSinoBIO, Pfizer Inc, Jiangsu Recbio Technology Co., Ltd., and others, are making investments in R&D activities in an effort to boost market demand.
The organization Pfizer Inc. (Pfizer) finds, creates, delivers, and markets biopharmaceuticals. The organization sells prescriptions for different circumstances, including cancer, inflammatory sicknesses, immune system issues, pain, metabolic, cardiovascular, and ladies' wellbeing concerns. Active pharmaceutical ingredients (APIs), biosimilars, clean injectable prescriptions, and agreement-producing administrations are additionally advertised. Pfizer disperses its merchandise through drug stores, government associations, individual supplier workplaces, medical clinics, centers, and wholesalers. Pfizer distributes its goods via pharmacies, government organizations, individual provider offices, hospitals, clinics, and distributors.
Pfizer contributed a total of $225 million to BioNTech's third partnership, which began in January 2022. By working together, we want to develop a shingles vaccine that makes use of RNA technology. Generating an mRNA-based shingles vaccine with shown safety and efficacy is the main objective of this collaboration. It is expected that clinical trials will begin in the second quarter of 2022, and both companies will split the costs related to the vaccine's development.
GSK plc (GSK) is a medical organization that spotlights the creation, production, and commercialization of general drugs, specialty medications, and immunizations. It offers drugs for the therapy of infections like HIV, respiratory, malignant growth, immuno-irritation, hostile to viral, focal sensory system (CNS), metabolic, cardiovascular, and urogenital, against bacterial, dermatology, and uncommon illnesses. The organization likewise presents over-the-counter (OTC) items for relief from discomfort, oral wellbeing, nourishment, skin wellbeing, and gastro-digestive sicknesses. GSK's antibody portfolio covers different sicknesses, including hepatitis, diphtheria, lockjaw, beating hack, rotavirus, HPV diseases, measles, and bacterial meningitis, among others.
The organization sells its items through wholesalers, drug stores, emergency clinics, doctors, and other gatherings around the world. GlaxoSmithKline plc's Shingles immunization got FDA clearance in July 2021 for use in anybody 18 years of age and older, especially people who are vulnerable to immunodeficiency or have compromised safe reactions because of various medicines or illnesses. GSK is focused on serving the enormous patient populace in danger of shingles and its related complexities by offering them effective vaccination substitutes.
Key companies in the Shingles Vaccine market include
Shingles Vaccine Industry Developments
February 2023: Pfizer Inc. and BioNTech SE started a phase 1/2 experiment to investigate the safety, tolerability, and immunogenicity of the firms' mRNA vaccine candidates against varicella-zoster virus (VZV), which causes shingles, a severe condition also known as herpes zoster or HZ.
February 2023: The adjuvanted recombinant shingles vaccine, REC610, has seen its first batch of subjects enrolled, according to Jiangsu Recbio Technology Co., Ltd.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 3.8 Billion |
| Market Size 2024 | USD 4.1 Billion |
| Market Size 2032 | USD 7.03 Billion |
| Compound Annual Growth Rate (CAGR) | 8.00% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Vaccine Type, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | GlaxoSmithKline plc., Merck & Co., Inc., SK chemicals, Green Cross Corp, Geneone Life Science, Vaccitech, CanSinoBIO, Pfizer Inc, and Jiangsu Recbio Technology Co., Ltd. |
| Key Market Opportunities | Rising mRNA-based vaccines and technological advancements |
| Key Market Dynamics | Increasing incidence of herpes zoster and increasing prevalence of shingles among adults |
Frequently Asked Questions (FAQ) :
The Shingles Vaccine market size was valued at USD 3.8 Billion in 2023.
The market is projected to grow at a CAGR of 8.00% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are GlaxoSmithKline plc., Merck & Co., Inc., SK Chemicals, Green Cross Corp, Geneone Life Science, Vaccitech, CanSinoBIO, Pfizer Inc, Jiangsu Recbio Technology Co., Ltd.
The Shingrix category dominated the market in 2023.
The Recombinant Vaccines category had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
